Qatar Biobank, a member of Qatar Foundation for Education, Science and Community Development, concluded its month-long summer internship on the ‘Qatar Genome Project’, attended by 5 female interns who are students and graduates of Qatar University and Weill Cornell Medical College in New York City.
After a competitive selection process which screened 22 applicants, 5 students were handpicked: Mariam Yasser Ali, Tala Hussam Ismail, and Tanzila Zenith enrolled in the biomedical sciences programme at Qatar University, in addition to Tasnim Fadl, a Qatar University medical science graduate and Njoud Al Naama, a Weill Cornell Medical College in New York City graduate currently working at Sidra Medical and Research Center.
Qatar Biobank supports Qatar Foundation’s mission to enhance national innovation in technology through medical research on prevalent health issues in Qatar and to encourage the local community to embrace a healthy lifestyle. Through its collection of samples and information on the health and lifestyles of a large number of the nation’s population, Qatar Biobank is making vital medical research possible for scientists in Qatar, the region, and the world.
The Qatar Genome Project was announced by Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation and Vice Chairperson of the Supreme Council of Health, during the World Innovation Summit on Health (WISH) 2013. The project seeks to assist in creating a roadmap for the study of genetics and its functions, and heralds a deep change in the future approach to treatment through personalised medicine.
Dr Asmaa Al-Thani, PhD, Head and Associate Professor of Biomedical Sciences and Vice Chairperson of the Board of Trustees of Qatar University said:
The internship represents the start of summer training series in Qatar Biobank, which offers a wealth of opportunities for students of different majors. In the future, the summer internship will include a scope of different fields such as science, law and IT.’
The summer internship, the first of its kind, created an opportunity for the interns to work on the pioneer Qatar Genome Project in which Qatar Biobank contributes as a member of Qatar’s National Genome Committee. A group of professors and researchers oversaw the summer training programme, headed by Dr Khalid A. Fakhro, Principal Investigator at Sidra Medical and Research Center and Assistant Professor at Weill Cornell Medical College in Qatar, along with Dr Nahla Afifi, Scientific and Education Director of Qatar Biobank.
Dr Nahla Afifi noted:
Qatar Biobank aims at serving the Qatari citizens by working towards discovering how life, the environment and genetics affect public health in the state. Such discoveries will help develop effective medical treatment and disease prevention, which will improve the health of future generations in Qatar.’
‘Through the Qatar Genome Project, Qatar Biobank works to create a roadmap for the future of treatment through personalised medicine. We organised this internship programme to provide an opportunity for students and graduates to be a part of the future by working on the Qatar Genome Project.’
During the internship period, the interns had the opportunity to participate in research based on the Qatari society’s perception and understanding of the Qatar Genome Project. Participants were also introduced to the ethical and legal aspects of the project. The interns worked on tracking and analysing genome projects around the world to learn about similar experiences and understand how other communities perceive them. Participants also researched better communication tactics that can be adopted to clarify the nature of this project and all its components to the Qatari community in the best way possible.
The results from the research conducted by the interns will be stored in a question bank, which will be of vital importance for studies conducted by researchers in the future.
The insight and information gathered by Qatar Biobank enables scientists to better understand why approximately 17% of our adult population suffers from type-2 diabetes, and customise the treatment that suits the unique genetic characteristics of each person in the coming years.